Why Ageing Clinical Trials Are Hard: David Weinkove at DoNotAge Conference 2026

Not every important conference session is about a molecule. David Weinkove’s DoNotAge Conference 2026 contribution focused on a problem that shapes the entire longevity field: how difficult it is to design clinical trials that can answer meaningful questions about ageing.

Why ageing is a difficult clinical endpoint

The official DoNotAge Conference 2026 highlights connect Weinkove’s contribution with the structural difficulties of ageing trials, including long time horizons, large participant requirements and the challenge of selecting endpoints that are meaningful within a realistic study duration.

Those constraints help explain why geroscience trials often use functional measures, biomarkers, disease-risk factors or biological-age estimates rather than waiting decades for lifespan endpoints.

Why methodology matters for supplement research

A short intervention can demonstrate a biomarker change without showing that people live longer or remain healthier for longer. Conversely, requiring lifespan data before considering any intermediate evidence would make many human geroscience questions impractical to study.

The useful question is whether the study design, endpoint, duration, population and statistical plan are appropriate for the claim being made.

What this means when reading longevity evidence

A protocol, biomarker study, animal experiment, registered trial and peer-reviewed human outcome answer different questions. Mechanistic or intermediate findings should not be converted into lifespan claims without evidence that supports that larger conclusion.

Source

Official DoNotAge Conference 2026 highlights

See the DoNotAge research, trials and grants tracker.